|
|
| |
For the treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes1
|
|
|
| |
|
| |
NEW JUBLIA:
An effective azole antifungal formulated to reach the site of infection1,2
JUBLIA delivers medication through, around, and under the toenail when applied as directed.1,2
| • |
In Study 1, JUBLIA achieved 17.8% (117/656) complete cure vs 3.3% (7/214) with vehicle1
|
| • |
In Study 2, JUBLIA achieved 15.2% (88/580) complete cure vs 5.5% (11/201) with vehicle1
|
| • |
Complete cure defined as 0% involvement of the target nail in addition to mycological cure, defined as both negative fungal culture and negative KOH1
|
JUBLIA is proven effective to restore fungus-free healthy nails1,2
Complete cure with JUBLIA
Condition of nails at baseline and at 52 weeks1,2
Study Design: In 2 identical, multicenter, randomized, parallel-group, double-blind, vehicle-controlled studies, patients with mild to moderate toenail distal lateral subungual onychomycosis (defined as 20%-50% clinical involvement of the target toenail, without dermatophytomas or matrix [lunula] involvement) were randomized to receive efinaconazole 10% solution or vehicle.1
Results are representative of patients who achieved complete cure. Photos have not been retouched. Individual results may vary.
|
|
|
|
| |
INDICATION
JUBLIA (efinaconazole) topical solution, 10% is indicated for the topical treatment of onychomycosis (tinea unguium) of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.
|
IMPORTANT SAFETY INFORMATION
|
| • |
JUBLIA is for topical use only and is not for oral, ophthalmic, or intravaginal use.
|
| • |
Patients should be instructed to contact their health care professional if a reaction suggesting sensitivity or severe irritation occurs.
|
| • |
The most common adverse reactions (incidence >1%) were (vs vehicle): ingrown toenail (2.3% vs 0.7%), application-site dermatitis (2.2% vs 0.2%), application-site vesicles (1.6% vs 0%), and application-site pain (1.1% vs 0.2%).
|
| • |
JUBLIA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and should be used with caution in nursing women. The safety and effectiveness in pediatric patients have not been established.
|
Click here for Prescribing Information or visit www.JubliaRx.com.
|
|
| |
| * |
Offer valid only for commercially insured patients whose insurance covers JUBLIA. Commercially insured patients whose insurance does not cover JUBLIA may pay more. Not valid for patients reimbursed in whole or part by federal health care programs, including Medicare, Medicaid, CHAMPUS, the Department of Veterans Affairs, state maternal and child health block grant programs under 42 U.S.C. 701 et. seq., state social service block grant programs under 42 U.S.C. section 1397 et. seq., or any other similar federal or state health care program. Void when prohibited by law, taxed, or restricted. Void outside the United States. See savings card for full eligibility terms and conditions here.
Patients with questions should call 855-264-0299.
|
References: 1. JUBLIA [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2014. 2. Data on file. Valeant Pharmaceuticals North America LLC. 3. Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013;68(4):600-608.
Except as otherwise indicated, all product names, slogans, and other marks are trademarks of the Valeant family of companies.
|
|
| |
| |
|
You have the right to opt out of receiving unsolicited advertisements by e-mail. You may contact us with your opt-out request, along with the e-mail to which your request relates, by telephone at 1-877-540-6501, or by submitting your request to valeantorder@corpcomm.com. Opt-out requests will be honored within 30 days of receipt. Please be sure to indicate the e-mail address to which your request relates and reason for opt-out.
© 2014 Valeant Pharmaceuticals North America LLC DM/JUB/14/0149
|
| |
|
|
